Alloplex has developed a differentiated, non-engineered, autologous cellular therapy derived, from peripheral blood mononuclear cells. SUPLEXA therapeutic cells display broad anti-tumor activity and are comprised of cells of both innate and adaptive phenotypes and as such employs a multi-modal anti-tumor strategy comprised entirely of normal activated immune cells.

The first in-human clinical trial, designed to yield both safety and efficacy data is anticipated to commence in 1Q 2022 and will enroll patients with a variety of hematologic malignancies and solid tumors.

The story behind Alloplex

Alloplex is led by its scientific founder and CEO, Dr. Frank Borriello MD, PhD – a Harvard-trained immunologist with 15 years in the pharmaceutical industry where he held position of increasing responsibility, beginning as a medical monitor for oncology clinical trials and later developing a keen interest and expertise Search and Evaluation and Business Development.

After a long hiatus from basic research, several unrelated elements coalesced to inspire Dr. Borriello to launch Alloplex Biotherapeutics.

The first element provided the scientific underpinning and stemmed from his realization that many immune pathways were reported in the literature to drive some level of anti-tumor benefit. Furthermore, that the molecular handles to these pathways were accessible in the form of protein ligands which could be used to specifically engage naturally occurring receptors on patient-derived white blood cells, thereby transforming them into tumor fighting cells.

The second element provided the motivation and came from the premature loss of his brother, Gaetano Borriello, PhD, an accomplished computer scientist, to colorectal cancer at age 56. The personal loss emphasized the huge unmet medical need still remaining in spite of the significant investment and high level of activity in cancer medicine.

The third and final element provided the serendipitous catalyst and came in the form of the purchase of the company where Dr. Borriello was employed as Head of Search and Evaluation. This event created a career inflection point and the unexpected opportunity to develop a company dedicated to the singular goal of developing an anti-tumor cellular therapy.

Alloplex people

Alloplex is led by a small and nimble senior management team bringing the advantage of long-term relationships and complementary skill sets to bear on a singular problem. These skillsets span immunology and analytical science, pharmaceutical development, clinical and regulatory expertise, and business development.

The senior leadership team

The corporate board

The scientific advisory board